Info

Palatin Technologies, Inc. is a biopharmaceutical company engaged in the development of peptide, peptide mimetic and small molecule compounds with a focus on melanocortin and natriuretic peptide receptor systems. As of June 30, 2008, the Company's products under development included PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of heart failure and hypertension; bremelanotide, a peptide melanocortin receptor agonist, for prevention of organ damage secondary to cardiac surgery; PL-6983, a peptide melanocortin receptor agonists, for treatment of female sexual dysfunction; melanocortin receptor-based compounds for treatment of obesity and related metabolic syndrome pursuant to an ongoing research collaboration and global license with AstraZeneca AB, and NeutroSpec, a radio-labeled monoclonal antibody product for imaging and diagnosing infection, which is the subject of a strategic collaboration agreement with the Mallinckrodt division of Covidien Ltd.(Source: 10-K)